Marker Therapeutics (MRKR) vs Shuttle Pharmaceuticals (SHPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Marker Therapeutics (MRKR) has outperformed Shuttle Pharmaceuticals (SHPH) over the past year, gaining 2.8% versus a loss of 78.2%. Marker Therapeutics is the larger company by market cap ($18.2 million vs $16.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRKR | SHPH |
|---|---|---|
| Share price | $1.09 | $3.49 |
| Market cap | $18.17M | $16.63M |
| 1-day change | -17.42% | -10.51% |
| YTD return | -26.85% | -80.61% |
| 1-year return | +2.83% | -78.19% |
| 5-year return | -91.14% | — |
| EPS (TTM) | $-0.39 | $-16.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.55M | — |
| Revenue growth (YoY) | -46.19% | — |
| Net income (latest FY) | $-12.16M | $-11.72M |
| Operating margin | -363.45% | — |
| Net margin | -342.96% | — |
| 52-week high | $2.46 | $44.40 |
| 52-week low | $0.81 | $2.58 |
| Distance from 52-week high | -55.69% | -92.14% |
| Analyst consensus | none | — |
| Avg. price target upside | +622.02% | — |
| Average volume | 711.96K | 41.80K |
| Shares outstanding | 16.67M | 4.76M |
| Employees | 5 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRKR has outperformed SHPH by 81.0 percentage points over the past year.
About Marker Therapeutics
MRKR stock →Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Shuttle Pharmaceuticals
SHPH stock →Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
MRKR vs SHPH FAQ
Which is bigger, Marker Therapeutics or Shuttle Pharmaceuticals?
Marker Therapeutics (MRKR) is larger, with a market capitalization of $18.17M compared with $16.63M for Shuttle Pharmaceuticals (SHPH).
Which stock has performed better over the past year, MRKR or SHPH?
MRKR returned +2.83% over the past 12 months, compared with -78.19% for SHPH (price return, excluding dividends). Past performance does not predict future results.
Are Marker Therapeutics and Shuttle Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.